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Objective. The epidemiology of Trichomonas vaginalis infection among sexually active socially-marginalized women in three urban,
coastal Peruvian cities was examined in order to quantify the prevalence of trichomonas infection and identify associated risk
factors. Methods. We conducted a cross-sectional, venue-based study of women from socially-marginalized populations in three
coastal Peruvian cities. Results. Among the 319 women enrolled, the overall prevalence of trichomonal infection was 9.1% (95% CI,
5.9%–12.3%). The mean age was 26.3 years, and 35.5% reported having had unprotected intercourse with nonprimary partners
and 19.8% reported two or more sex partners in the last three months. Trichomonal infection was associated with increased
number of sex partners (PR 2.5, 95% CI 1.4–4.6) and unprotected sex with nonprimary partner in the last three months (PR
2.3, 95% CI 1.1–4.9). Conclusions. A moderately high prevalence of trichomonal infection was found among women in our study.
Trichomonal infection was associated with unprotected sex and multiple sex partners. Efforts to control the continued spread of
trichomonal infection are warranted.
Copyright © 2009 Segundo R. Leon et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Intoduction
Trichomonas vaginalis infection is one of the most com-
mon curable sexually transmitted infections [1]. WHO
estimates that 173 million of new cases occur annually
[2]. Trichomonal infection has been associated with adverse
reproductive health outcomes including pelvic inflammatory
disease, low infant birth weight and premature delivery
[3–6]. Untreated infection can persist up to 5 years [7].
Furthermore, Trichomoniasis has been shown to increase
transmission and acquisition of other sexually transmitted
diseases, including HIV infection [1, 8, 9]. The frequency
of trichomonal infection is not monitored in most countries
nor do control programs exist. Peruvian STI guidelines do
not include trichomonas diagnostic testing; the syndromic
management of suspected vaginal trichomoniasis is the
current standard for clinical care [10]. Trichomonal infection
is most likely more common among women and men
than is generally understood, and long standing, asymp-
tomatic infections may lead to continued community level
transmission. As Trichomonas prevalence depends on many
factors such as age, sexual activity, and the number of sex
partners, a better understanding of the epidemiology of
this infection in women is needed to foster disease control
programs in populations at risk for reproductive health
complications.
2. Methods
2.1. Study Design and Participant Enrollment. This study was
a cross-sectional analysis of the behavioral and biological
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data from the baseline assessment of a cohort subsequently
enrolled in the NIMH Collaborative HIV/STD Preven-
tion Trial collected from 2003 to 2005 in Peru [11]. We
enrolled participants from low-income neighborhoods in
three coastal Peruvian cities: Lima, Trujillo, and Chiclayo.
We chose neighborhoods based on data from the Peru-
vian National Institute of Statistics and Informatics [12].
Study staff visited selected neighborhoods to recruit socially
marginalized women. Socially marginalized women were
characterized through informal interviews and participant
observation, and based on ethnographic information col-
lected prior to the study baseliness were shown to have
high levels of sexual risk behaviors. We defined socially
marginalized women as those women living in low-income
neighborhoods “who contradicted Peruvian social norms by
spending time with and having sex with poor unemployed
men.” Most of these women were also unemployed, and
although the majority reported a stable sex partner, most
of them also reported having multiple sex partners, further
defying the social norms of Peru [13].
Eligible women were recruited by outreach workers from
venues such as volleyball fields, hair salons, parks, bars, and
street corners. The number of venues selected per city was
approximately proportional to the city’s overall population.
Eligible participants were restricted to women between 18
and 40 years of age who reported having had sex in the past
six months, intended to stay in the neighborhood for at least
two years, and who frequented the target venue at least twice
a week.
All eligible women who signed informed consent were
enrolled.
2.2. Data Collection. Participants were invited to a tempo-
rary project office in their neighborhood, where we privately
administered a 30-minute structured survey in Spanish,
wherein trained interviewers read questions to participants
and entered their answers into a portable computer. The
survey instrument collected sociodemographic information
as well as detailed sexual risk behavior with the last five
sex partners, number of sex partners, STI-related symptoms,
alcohol and drug, use and HIV status.
Upon completing the survey, participants underwent
pretest counseling for STIs including HIV infection, con-
ducted by a trained counselor. Trained laboratory technicians
then explained to each participant how to self-collect a
vaginal specimen using a dacron swab. A second dacron
swab was stored for Chlamydia trachomatis and Neisseria
gonorrhoeae PCR testing (CT/NG Amplicor PCR, Roche
Diagnostics, NJ, USA), and a blood sample was also collected
for HIV-1 (Genetic Systems Bio-Rad Laboratories, Hercules,
Calif, USA), Herpes Virus Simplex Type 2 antibodies
(HerpeSelect; Focus Technologies, Cypress, Calif, USA), and
syphilis testing (RPRnosticon, Shield Diagnostics, Dundee,
UK and Serodia-TPPA, Fujirebio Diagnostics Inc, Tokyo,
Japan). Participants returning for results underwent posttest
counseling to ensure their understanding of the meaning of
both positive and negative results and for treatment in case
of a positive result. Treatment for trichomoniasis consisted
of 2 g, single dose metronidazole by mouth administered
by trained health personnel. All participants with positive
results were encouraged to share test results with recent sex
partners. Reimbursement for travel costs and time spent
during the assessment was given to each participant at the
rate of 15 Peruvian Soles (approximately $5) at their first visit
and an additional 10 Peruvian Soles (approximately $3) at
their posttest visit.
2.3. Laboratory Methods for Trichomonas vaginalis Detection.
All vaginal swab specimens were immediately inoculated
and transported at ambient temperature using the In Pouch
TV culture media (Biomed Diagnostics, White City, Ore,
USA) to the Cayetano Heredia University—Sexual Health
Laboratory in Lima, Chiclayo, or Trujillo. Cultures were
transported to the laboratory within 6–8 hours after sample
collection and incubated at 37◦C once they arrived at the
laboratory. To monitor the performance of test and as part of
the quality control of the study, known positive samples were
inoculated in the field, transported, and cultured under the
same conditions. All samples, including the controls, were
observed microscopically at 400x power for the presence
of motile, oval flagellated protozoan daily for 5 days. The
observation of motile trichomonads was reported as positive,
and specimens showing no organisms after 5 days of
incubation were considered negative for T. vaginalis.
Laboratory work was performed in accordance with
the College of American Pathology Quality Assurance and
Quality Control program.
2.4. Data Analysis. Trichomonal infection was the primary
outcome of interest. Explanatory variables included demo-
graphic characteristics and sexual and drug using behaviors.
Categorization of continuous variables was based on the dis-
tribution of data. As odds ratios overestimate the estimated
risk when the prevalence is high, we calculated prevalence
ratios to avoid that bias [14]. To model the prevalence
ratios we used Poisson family generalized linear models and
adjusted the standard errors to account for the clustered
nature of sample. Multivariate models were created taking
into account all variables that were significant at P-value
<.1 in bivariate analysis [14]. The variables added to the
multivariate model were selected based on likelihood ratio
tests comparing nested to saturated models and included
only if the likelihood ratio test had a P-value <.05. All
statistical analyses were conducted in Stata 9.2 (College St.
Tex, USA).
2.5. Human Subjects. The study was approved by the Com-
mittee on Human Research of the University of California,
San Francisco; University of California, Los Angeles; Naval
Medical Research Center Detachment and Cayetano Heredia
University of Peru. We collected data only from participants
that gave written informed consent to participate in the
study.
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Figure 1: Prevalence of trichomonas among socially-marginalized
women by age category in urban coast Peru, 2003–2005.
3. Results
Between 2003 and 2005, we recruited and assessed 308
women from 20 low-income communities in coastal Peru.
The overall prevalence of T. vaginalis infection by culture was
9.1% (95% CI, 6.1%–12.9%). The median age of the women
was 24 years (IQR, 21–31). Demographic and risk behavior
characteristics are described in detail in Table 1.
Women with T. vaginalis infection were more likely to
be older; the highest prevalence was found in the oldest
age group, 36–40 years (Figure 1). Those with less education
were 3 times more likely to have trichomonal infection
compared to those who completed high school, and being
single was associated with having trichomonal infection
(Table 1). The prevalence of trichomonal infection among
women with vaginal discharge and painful urination in the
prior six months was lower than the prevalence among
those who did not report vaginal discharge during the same
period, although the difference was not statistically signif-
icant. Women with HSV-2 infection and syphilis infection
were twice as likely to have trichomonal infection. In the
multivariate model, because only the number of partners in
the past 6 months significantly improved the model, no other
variables were entered into the model.
4. Discussion
We found a moderately high prevalence of T. vaginalis infec-
tion among socially-marginalized young women from low-
income communities in coastal Peru. T. vaginalis infection
occurred more often among older women (See Figure 1),
women who had not completed high school, single women,
women who reported unprotected sex with a nonsteady
partner, and women who reported multiple sex partners. No
association was found between any vaginal symptoms and T.
vaginalis.
While most epidemiological studies on trichomonal
infection have been focused on pregnant women, adoles-
cents, and female sex workers accessing care, there are few
studies at the population-level and in particular, socially-
marginalized women [5, 15–19]. Our findings are important
because such hard to reach populations are often under-
represented because they are not seeking health care and
represent a high-risk target population and potential core
population that maintain endemic trichomonal infections
at the population level. In Latin America trichomonal
prevalence has varied from 2.9% to 16.5%, where the
highest prevalence was found in population samples in the
jungle and the highlands of Peru´, and the lower prevalences
were found in clinical settings such as family planning
clinics, pharmacies, and obstetrics services. In general, tested
populations in those studies were most often symptomatic
women [15, 20, 21].
We found a strong association between trichomonal
infection and increased age. The association between higher
prevalence of trichomonal infection and older age is unusual
for nonviral sexually transmitted infections. Chlamydia and
gonorrhea are more prevalent in younger female popula-
tions. The increased prevalence of trichomonal infection in
older women suggests long-term prevalent infection that
does not spontaneously resolve and would be missed by
screening programs focused on younger age women [22].
The prevalence of trichomonal infection was not dif-
ferent between women with or without presence of recent
painful urination or vaginal discharge. That finding suggests
that syndromic management of T. vaginalis may result in
both over and under treatment. The asymptomatic nature
of trichomonal infection also could contribute to a long
duration of infection and continued spread of infection
in the population [1, 7, 23]. Our data, and others [4,
21, 24], attest to the asymptomatic nature of T. vaginalis
and the need for screening and treatment programs to
control the spread of trichomonal infection. Results from
other Peruvian studies as well as the results in the present
study indicate that there is no direct relationship between
T. vaginalis infection and symptoms making syndromic
treatment unlikely to impact the population burden of
infection [20, 21].
Our analysis had several limitations. First, the sample size
was small resulting in limited power to assess multivariate
models between demographic and behavioral characteristics
and T. vaginalis. Furthermore, the results presented here
may not be generalizable to other female populations. While
response bias is always a concern, we believe that the use of
standardized interviews by trained staff helped to minimize
social desirability and other information biases. Importantly
as all epidemiologic information was collected prior to
testing, there was no reason to suspect differential bias
associated by trichomonal infection. Selection bias was also a
concern, but because most women were asymptomatic we do
not believe that those with potential trichomonal infection
were more likely to participate compared with those without
infection.
Since T. vaginalis is a common sexually transmitted
pathogen, the screening and treatment of sex partners
of infected women must be also prioritized as a public
health measure to prevent reinfection and reduce infection
prevalence and complications in untreated males [23, 25]. As
the majority of the assessed population in this study was in a
fertile age range, our findings support the need for improved
disease control activities to reduce adverse trichomoniasis-
associated reproductive health outcomes such as ectopic
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Table 1: Demographics, risk factors, and prevalence of T. vaginalis infection among women from low-income communities of urban coastal
Peru, 2003–2005 (N = 319).
No. (%) Trichomonas vaginalis prevalence (%) Prevalence ratio P-value
Demographics
Reported age (years)
18–20 75 (23.5) 10.7 1
21–25 100 (31.4) 8.0 0.8 (0.3–2.3) 0.61
26–30 59 (18.4) 6.8 0.6 (0.2–2.2) 0.49
31–35 50 (15.7) 8.0 0.8 (0.2–2.7) 0.67
36–40 35 (11.0) 14.3 1.3 (0.5–3.9) 0.59
High school education
Yes 129 (40.6) 7.8 1
No 189 (59.4) 10.1 1.3 (0.9–1.9) 0.171
Marital status
Married 162 (50.8) 6.8 1
Single 115 (36.0) 13.9 2.0 (0.9–4.5) 0.08
Other (separated, widowed, divorced) 42 (13.2) 4.8 0.7 (0.2–3.2) 0.65
Risk behavior
Years sexual activity
0–5 94 (30.5) 9.7 1
6–10 89 (28.9) 6.7 0.7 (0.3–1.8) 0.45
11–15 58 (18.8) 8.6 0.9 (0.4–2.1) 0.79
16–20 39 (12.7) 10.3 1.1 (0.3–3.5) 0.92
21-more 28 (9.1) 14.3 1.5 (0.6–3.6) 0.38
Number of sex partners in last six months
0-1 220 (71.4) 6.4 1
2+ 80 (28.6) 15.9 2.5 (1.4–4.6) <0.01
Months living with partner
0–6 months 17 (11.26) 17.65 3.4 (0.9–13.3) 0.08
6–12 months 134 (88.74) 5.97 1
Smoked cocaine paste, 30 days
No 309 (96.9) 8.4 1
Yes 10 (3.1) 30.0 3.6 (1.3–10.1) 0.02
Any sex last 3 months with nonsteady partner
No 193 (60.7) 6.2 1
Yes 125 (39.3) 12.8 2.1 (1.0–4.3) 0.06
Unprotected sex last 3 months with nonsteady partner
No 209 (65.7) 6.7 1
Yes 109 (34.3) 13.8 2.1 (1.1–4.0) 0.04
Symptoms
Episode of painful urination in the last 6 months
No 185 (58.0) 9.7 1
Yes 134 (42.0) 8.2 0.8 (0.4–1.7) 0.63
Episode of vaginal discharge in the last 6 months
No 215 (67.6) 10.7 1
Yes 103 (32.4) 5.8 0.5 (0.2–1.8) 0.32
STIs
HIV-1
No 318 (99.7) 9.1
Yes 1 (0.3) 0.0 Undefined
HSV-2
No 179 (57.9) 6.7 1
Yes 130 (42.1) 13.1 2.0 (1.1–3.5) 0.03
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Table 1: Continued.
No. (%) Trichomonas vaginalis prevalence (%) Prevalence ratio P-value
Syphilis
No 307 (96.2) 8.8 1
Yes 12 (3.8) 16.7 1.9 (0.8–4.5) 0.15
Chlamydia
No 274 (85.9) 8.4 1
Yes 45 (14.1) 13.3 1.6 (0.8–3.0) 0.15
Gonorrhea
No 306 (97.1) 9.2
Yes 9 (2.9) 0.0 Undefined
pregnancy, low infant birth weight, preterm labor, and non-
HPV associated cervical neoplasia [14, 26, 27]. As T. vaginalis
is widely prevalent and one of the easiest infections to treat
with an inexpensive antimicrobial, further studies are needed
to determine if screening and treatment of trichomoniasis
will improve the reproductive health and birth outcomes of
women.
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